CytomX Therapeutics Inc

CytomX Therapeutics Inc operates as an oncologyfocused biopharmaceutical company in the United States The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer The companys product candidates include CX2009 an antibody drug conjugates ADC against CD166 which is in Phase II clinical trials for the treatment of breast cancer CX2029 that is in Phase II clinical trials for the treatment of squamous nonsmall cell lung cancer head and neck squamous cell carcinoma esophageal and gastroesophageal junction cancers and diffuse large Bcell lymphoma BMS986249 a CTLA4 Probody therapeutic drug which is in Phase III clinical trials for the treatment of metastatic melanoma and BMS986288 an antiCTLA4 Probody drug which is in Phase I clinical trials for the treatment of solid tumors It also develops CX2043 a conditionally activated ADC targeting the epithelial cell adhesion molecule as well as CX904 a conditionally activated epidermal growth factor receptor for the treatment of solid tumor The company has strategic collaborations with AbbVie Ireland Unlimited Company Amgen Inc BristolMyers Squibb Company ImmunoGen Inc Pfizer Inc and Astellas Pharma Inc to develop Probody therapeutics CytomX Therapeutics Inc was founded in 2008 and is headquartered in South San Francisco California